Description
Phase
Phase 2 - takes the treatment one step further, assessing the activity of a particular therapy in a disease, often building upon leads from the Phase I trial. While patients are generally required to be previously untreated, participation in a Phase II trial doesn't usually preclude the patient from getting the standard treatment after they've received the investigational agent. At best they are allowed to get a new drug they wouldn't be able to get otherwise that may turn out to be better for their disease.Inclusion and Exclusion Criteria
Please contact Heberto Santos to learn more about the eligibility criteria for this trial. Please use the contact form on the right side.
Sites
-
California
- USC Norrris Cancer Center, Los Angeles, California, 90033
- USC Norrris Cancer Center, Los Angeles, California, 90033
- City of Hope Comprehensive Cancer Ctr, Duarte, California, 91010
- City of Hope Comprehensive Cancer Ctr, Duarte, California, 91010
- Bay Area Cancer Research Group, Pleasant Hill, California, 94523
- Bay Area Cancer Research Group, Pleasant Hill, California, 94523
-
Oregon
- Oregon Health and Science University, Portland, Oregon, 97239
-
Kansas
- University of Kansas Cancer Center, Westwood, Kansas, 66205
-
Texas
- MD Anderson, Houston, Texas, 77030
- MD Anderson, Houston, Texas, 77030
-
Missouri
- Mercy Medical Research Center, Springfield, Missouri, 65807
- Mercy Medical Research Center, Springfield, Missouri, 65807
-
Minnesota
- Mayo Clinic, Rochester, Minnesota, 55905
-
Wisconsin
- Medical College of Wisconsin-Froedtert Cancer Center, Milwaukee, Wisconsin, 53226
- Medical College of Wisconsin-Froedtert Cancer Center, Milwaukee, Wisconsin, 53226
-
Illinois
- The University of Chicago, Chicago, Illinois, 60637
- The University of Chicago, Chicago, Illinois, 60637
-
Indiana
- Inidana Univ Simon Cancer Center, Indianapolis, Indiana, 46202
- Inidana Univ Simon Cancer Center, Indianapolis, Indiana, 46202
-
Georgia
- Emory University, Atlanta, Georgia, 30322
Powered by
SC CTSI